Citius Pharmaceuticals, Inc. (CTXR)
USD 2.59
(-5.13%)
USD 2.59
(-5.13%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -29.06 Million | -28.36 Million | -24.25 Million | -16.93 Million | -12.43 Million | -11.31 Million |
| Net Income | -32.54 Million | -33.64 Million | -23.05 Million | -17.54 Million | -15.56 Million | -12.53 Million |
| Depreciation & Amortization | 194.31 Thousand | 179.67 Thousand | 164.86 Thousand | 152.36 Thousand | 893.00 | 1753.00 |
| Deferred income taxes | 576 Thousand | 576 Thousand | -166.55 Thousand | - | - | -450 Thousand |
| Stock-based compensation | 6.61 Million | 3.9 Million | 1.45 Million | 803.26 Thousand | 715.98 Thousand | 779.7 Thousand |
| Change in working capital | -4 Million | 239.55 Thousand | -2.71 Million | -866.96 Thousand | 2.19 Million | 509.84 Thousand |
| Other non-cash items | 102 Thousand | 378.2 Thousand | 68 Thousand | 528.77 Thousand | 211.59 Thousand | 377.2 Thousand |
| Investing Cash Flow | - | - | -40 Million | -1831.00 | - | - |
| Investments in PPE | 2.00 | - | -40 Million | -1831.00 | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -40 Thousand | - | - | - |
| Financing Cash Flow | 13.82 Million | - | 120.47 Million | 22.89 Million | 11.14 Million | 17.29 Million |
| Debt repayment | - | - | -172.97 Thousand | -164.58 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 13.79 Million | - | 89.43 Million | 15.57 Million | 11.12 Million | 16.17 Million |
| Other Financing Activities | 31.26 Thousand | - | 31.21 Million | 7.48 Million | 23.21 Thousand | 1.12 Million |
| Accounts receivables | - | - | - | - | 818.34 Thousand | -818.34 Thousand |
| Accounts payables | 1.76 Million | -111.71 Thousand | -579.14 Thousand | -857.3 Thousand | 1.14 Million | 971.01 Thousand |
| Inventory | - | - | - | - | -818.34 Thousand | - |
| Other working capital | -5.76 Million | 351.27 Thousand | -2.13 Million | -9661.00 | 1.05 Million | -461.16 Thousand |
| Cash at beginning of period | 41.71 Million | 70.07 Million | 13.85 Million | 7.89 Million | 9.18 Million | 3.2 Million |
| Cash at end of period | 26.48 Million | 41.71 Million | 70.07 Million | 13.85 Million | 7.89 Million | 9.18 Million |
| Capital Expenditure | 2.00 | - | -40 Million | -1831.00 | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -15.23 Million | -28.36 Million | 56.21 Million | 5.96 Million | -1.29 Million | 5.97 Million |
| Free Cash Flow | -29.06 Million | -28.36 Million | -64.25 Million | -16.93 Million | -12.43 Million | -11.31 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -10.57 Million | -8.54 Million | -9.23 Million | -9.94 Million | -32.54 Million | -8.47 Million |
| Depreciation & Amortization | 52.84 Thousand | 52.07 Thousand | 51 Thousand | 49.96 Thousand | 194.31 Thousand | 49.01 Thousand |
| Deferred income taxes | 144 Thousand | 144 Thousand | 144 Thousand | 144 Thousand | 576 Thousand | 144 Thousand |
| Stock-based compensation | 3.06 Million | 3.07 Million | 3.05 Million | 3.07 Million | 6.61 Million | 1.17 Million |
| Change in working capital | -1.16 Million | -2.61 Million | -233.46 Thousand | -126.19 Thousand | -4 Million | -2.47 Million |
| Other non-cash items | 4.28 Million | 3.25 Million | 76.14 Thousand | 3.32 Million | 102 Thousand | 918.07 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | -4.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 13.71 Million | - | - | -687.00 | 13.82 Million | 13.79 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | -31.95 Thousand | 13.79 Million | 13.79 Million |
| Other Financing Activities | 13.71 Million | - | - | 31.26 Thousand | 31.26 Thousand | 13.79 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -1 Million | 22.25 Thousand | -280.08 Thousand | -152.33 Thousand | 1.76 Million | 354.07 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -156.42 Thousand | -2.63 Million | 46.61 Thousand | 26.14 Thousand | -5.76 Million | -2.82 Million |
| Cash at beginning of period | 12.55 Million | 20.34 Million | 26.48 Million | 33.28 Million | 41.71 Million | 29.06 Million |
| Cash at end of period | 17.91 Million | 12.55 Million | 20.34 Million | 26.48 Million | 26.48 Million | 33.28 Million |
| Capital Expenditure | -4.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 5.35 Million | -7.78 Million | -6.13 Million | -6.8 Million | -15.23 Million | 4.21 Million |
| Free Cash Flow | -8.36 Million | -7.78 Million | -6.13 Million | -6.8 Million | -29.06 Million | -9.58 Million |
DUERF
OKEPF
NOVO-B
9830
603341
5112